APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Basecare Medical Device / Equity Capital Markets

<div>
<p><a href="https://www.smartkarma.com/entities/basecare-medical-device-co-l" target="_blank" data-smartkarma-citation="entities:31086:1" rel="noopener">Basecare Medical Device Co L (2170 HK)</a> raised about US$235m at HK$27.36 per share, the top-end of its IPO price range. </p>
<p>Basecare Medical (Basecare) is a genetic testing solutions provider for assisted reproduction in China. The company’s current core product, PGT-A kit, is the first and only third-generation IVF genetic test kit approved by the National Medical Products Administration (NMPA) in February 2020.</p>
<p>Our previous coverage of the IPO:</p>
</div>
<div>
<ul>
<li>
<a href="https://www.smartkarma.com/insights/basecare-medical-pre-ipo-genetic-testing-leader-in-china" target="_blank" data-smartkarma-citation="insights:47361" rel="noopener">Basecare Medical (贝康医疗) Pre-IPO - Genetic Testing Leader in China</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/basecare-medical-ipo-a-leader-in-the-making" target="_blank" data-smartkarma-citation="insights:47427" rel="noopener">Basecare Medical (贝康医疗) IPO - A Leader in the Making</a> </li>
</ul>
</div>


Basecare Medical Device Co L (2170 HK) raised about US$235m at HK$27.36 per share, the top-end of its IPO price range. 
Basecare Medical (Basecare) is a genetic testing solutions provider for assisted reproduction in China. The company’s current core product, PGT-A kit, is the first and only third-generation IVF genetic test kit approved by the National Medical Products Administration (NMPA) in February 2020.
Our previous coverage of the IPO:




Basecare Medical (贝康医疗) Pre-IPO - Genetic Testing Leader in China 

Basecare Medical (贝康医疗) IPO - A Leader in the Making 



Basecare Medical (贝康医疗) IPO Trading - Poised for a Strong Debut